60 Degrees Pharmaceuticals Inc WT (SXTPW)

Feb 2, 2026, 8:01 AM EST - 22 days ago

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

Jan 15, 2026, 8:01 AM EST - 5 weeks ago

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

Dec 29, 2025, 8:01 AM EST - 2 months ago

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Dec 11, 2025, 8:01 AM EST - 2 months ago

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

Nov 21, 2025, 8:01 AM EST - 3 months ago

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

Nov 13, 2025, 1:51 PM EST - 3 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Oct 15, 2025, 7:14 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Oct 9, 2025, 7:04 AM EDT - 4 months ago

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Sep 3, 2025, 8:02 AM EDT - 6 months ago

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Aug 21, 2025, 8:31 AM EDT - 6 months ago

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 19, 2025, 8:54 AM EDT - 6 months ago

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Aug 13, 2025, 4:14 PM EDT - 6 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

Jul 16, 2025, 4:01 PM EDT - 7 months ago

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 15, 2025, 9:10 AM EDT - 8 months ago

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025, 7:01 AM EDT - 8 months ago

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jun 4, 2025, 8:56 AM EDT - 9 months ago

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

Jun 3, 2025, 8:49 AM EDT - 9 months ago

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

May 15, 2025, 4:31 PM EDT - 10 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Apr 22, 2025, 8:44 AM EDT - 11 months ago

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Apr 10, 2025, 8:31 AM EDT - 11 months ago

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Apr 8, 2025, 8:31 AM EDT - 11 months ago

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

Feb 21, 2025, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

FTHM

Feb 20, 2025, 10:36 AM EST - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

Feb 11, 2025, 12:59 PM EST - 1 year ago

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

Feb 6, 2025, 2:07 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 5, 2025, 9:22 AM EST - 1 year ago

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 30, 2025, 2:20 PM EST - 1 year ago

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 28, 2025, 8:01 AM EST - 1 year ago

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Jan 8, 2025, 8:02 AM EST - 1 year ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Dec 23, 2024, 8:57 AM EST - 1 year ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

Dec 11, 2024, 8:56 AM EST - 1 year ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's Hospital

Dec 2, 2024, 4:05 PM EST - 1 year ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VSEE

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CANF

Nov 14, 2024, 2:31 PM EST - 1 year ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Oct 3, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Sep 12, 2024, 7:19 AM EDT - 1 year ago

Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying

HYLN COCH

Sep 4, 2024, 8:00 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Aug 28, 2024, 2:48 PM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Aug 14, 2024, 11:01 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Aug 12, 2024, 9:12 AM EDT - 1 year ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

Aug 6, 2024, 9:26 AM EDT - 1 year ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

Jul 25, 2024, 9:02 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

Jul 19, 2024, 8:29 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Jul 9, 2024, 6:31 AM EDT - 1 year ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

Jun 27, 2024, 7:59 AM EDT - 1 year ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

May 30, 2024, 7:59 AM EDT - 1 year ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

May 20, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

May 15, 2024, 1:45 PM EDT - 1 year ago

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

May 8, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

May 2, 2024, 7:59 AM EDT - 1 year ago

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required